MKMasafumi Kurajoh

Masafumi Kurajoh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masafumi Kurajoh has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • Hidenori Koyama

    Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

    8 shared publications
  • Takuhito Shoji

    Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

    6 shared publications
  • Tetsuya Yamamoto

    Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine

    6 shared publications
  • Hirokazu Okazaki

    Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.

    3 shared publications
  • Masaaki Inaba

    Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

    3 shared publications
  • Masaaki Inaba

    Ohno Memorial Hospital, Osaka, Japan

    3 shared publications

Latest Publications

  • Open Access

    Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model

    by Yuki Nagata, Yasuo Imanishi, Tomomi Tateishi, Daichi Miyaoka, Masafumi Kurajoh, Andrew Arnold, Masanori Emoto

    Parathyroid hormone (PTH) increases fibroblast growth factor 23 (FGF23), mediated both by protein kinase A (PKA) and Wnt signaling, and decreases expression of sclerostin, a Wnt antagonist derived from osteocytes. Patients with primary hyperparathyroidism (PHPT) have lower serum sclerostin levels than healthy controls, consistent with the idea of SOST downregulation by PTH. Nevertheless, the relationship between FGF23 and sclerostin in PHPT is still unclear. We examined this issue in a mouse model of PHPT. PHPT mice had increased FGF23 and decreased sclerostin expression in calvaria and in their serum concentrations compared with wild-type (WT) mice. In UMR106 osteoblasts, PTH increased Fgf23 expression and decreased Sost expression, as well as forskolin, a PKA agonist, whereas inhibition of PKA reversed the changes in Fgf23 and Sost expression, stimulated by PTH. Sclerostin treatment had no effect on Fgf23 expression, but when it was added together with PTH, it statistically significantly abrogated the increase in Fgf23 expression. By contrast, there was no statistically significant correlation between serum FGF23 and sclerostin, whereas PTH was positively and negatively correlated with serum FGF23 and sclerostin, respectively. These results indicate that the high level of PTH in PHPT mice leads to increased FGF23 and decreased sclerostin expression in serum and calvaria. A decrease of sclerostin may further augment FGF23 in vitro; however, there was no statistically significant association between circulating FGF23 and sclerostin. It is suggested that the pathogenesis of increased FGF23 expression in PHPT mice may be modified by not only sclerostin, but also other regulatory factors modulated by PTH.


  • Open Access

    Attenuated Dentin Matrix Protein 1 Enhances Fibroblast Growth Factor 23 in Calvaria in a Primary Hyperparathyroidism Model

    by Yuki Nagata, Yasuo Imanishi, Masaya Ohara, Tomomi Maeda-Tateishi, Daichi Miyaoka, Noriyuki Hayashi, Masafumi Kurajoh, Masanori Emoto, Masaaki Inaba

    Fibroblast growth factor 23 (FGF23) secretion is facilitated by the PTH, particularly in hyperparathyroidism. The PTH also attenuates dentin matrix protein 1 (DMP1), which is produced by osteocytes to contribute to bone mineralization and suppress FGF23 expression. Nevertheless, it remains unknown whether attenuated DMP1 affects FGF23 expression in hyperparathyroidism. We examined their expression in bone tissue using a mouse model of primary hyperparathyroidism (PHPT). PHPT mice increased serum FGF23 levels, along with a high level of serum PTH. Fgf23 expression increased, and Dmp1 decreased significantly in the calvaria of PHPT mice compared with wild-type mice and primary osteoblasts treated with PTH. In UMR106 mature osteoblasts, PTH increased Fgf23 expression and decreased Dmp1 expression, and stimulation of protein kinase A (PKA) signaling by forskolin also increased Fgf23 expression and decreased Dmp1 expression in a dose-dependent manner, whereas inhibition of PKA signaling with 10−5 M H89 reversed the changes in Fgf23 and Dmp1 expression when cells were stimulated with PTH. Silencing Dmp1 along with PTH treatment led to an additive increase in Fgf23 expression, accompanied by additive phosphorylation of the cAMP-response element-binding protein. These results indicate that persistent and high levels of PTH lead to the continuous activation of PKA signaling in osteoblasts/osteocytes, resulting in an increase in FGF23 and a decrease in DMP1 in bone. Moreover, suppression of DMP1 enhanced FGF23 expression in PHPT, besides having a direct effect on PTH. These mechanisms may describe one of the pathogeneses behind the increase in FGF23 transcription in bone tissue in patients with PHPT.


  • 血液透析患者においてプリノール服用は骨密度と関連する

    by Masafumi Kurajoh, Senji Okuno, Jinrou Miyawaki, Hisanori Okazaki, Shigeichi Shoji, Tomoyuki Yamakawa, Eiji Ishimura, Masaaki Inaba

  • Open Access

    Yogurt containing Lactobacillus gasseri PA-3 alleviates increases in serum uric acid concentration induced by purine ingestion: a randomized, double-blind, placebo-controlled study

    by Masafumi Kurajoh, Yuji Moriwaki, Hidenori Koyama, Hiroshi Tsuboi, Hirotaka Matsuda, Naruomi Yamada, Chizuru Saito, Hiroshi Kano, Yukio Asami, Tetsuya Yamamoto

    Objective: Ingestion of yogurt containing Lactobacillus gasseri PA-3 (PA-3, Accession No: NITE BP-224) (PA-3Y) has been shown to reduce serum uric acid (SUA) levels by interfering with the intestinal absorption of food-derived purines in animal studies. To confirm this mechanism in humans, the ability of PA-3 intake to alleviate purine ingestion-induced increases in SUA levels was analyzed. Research Methods and Procedures: In this randomized, double-blind, placebo-controlled crossover study, 16 healthy adults were randomized to groups ingesting of 112 g of PA-3Y or yogurt without PA-3 (control yogurt) in addition to standardized meals for 3 days. Purine-loading tests, in which subjects ingested 112 g of PA-3Y or control yogurt followed immediately by 498 mg of a mixture of purine nucleotides, were performed on the fourth day of each test period. Blood and urine samples were collected before and after the purine-loading tests. Results: The increase in the SUA concentration from the baseline was significantly lower following the ingestion of PA-3Y than of control yogurt alone, especially at 30 (P=0.033) and 60 (P=0.028) minutes. In addition, the area under the curve for the increase in the SUA concentration from the baseline to 150 minutes was also significantly lower (P=0.041) in the PA-3Y than in the control yogurt group. However, urinary and fractional excretions of uric acid were not different between the two groups. Conclusion: The ingestion of PA-3 before purine intake alleviates the increase in SUA levels, probably by reducing purine absorption in the intestine, and not by enhancing urinary excretion of uric acid.


  • 人間ドック受診者におけるキサンチン酸化還元酵素活性と糖代謝との関連

    by Masafumi Kurajoh, Shinya Fukumoto, Yuki Nagata, Shinya Nakatani, Masahiro Tsuda, Koka Motoyama, Tomoaki Morioka, Shinsuke Yamada, Katsuhito Mori, Yasuo Imanishi, et al.

  • Open Access

    Hypokalemia associated with pseudo-Cushing’s syndrome and magnesium deficiency induced by chronic alcohol abuse

    by Masafumi Kurajoh, Keiko Ohsugi, Miki Kakutani-Hatayama, Takuhito Shoji, Hidenori Koyama

    Hypokalemia and hypomagnesemia are frequently observed in patients with chronic alcoholism. However, the involvement of deranged cortisol regulation in patients with those conditions has not been reported. A 63-year-old Japanese male with chronic alcoholism was referred to the Department of Diabetes, Endocrinology and Metabolism for examination and treatment of hypokalemic periodic paralysis. Laboratory findings showed hypokalemia (2.3 mmol/l), as well as a high level of urinary excretion of potassium and hypomagnesemia (1.2 mg/dl), whereas urinary excretion of magnesium was undetectable. Potassium infusion treatment recovered that level in serum to 4.1 mmol/l, though it decreased to 2.2 mmol/l following discontinuation. A dexamethasone suppression test and urinary cortisol level showed corticotropin-dependent hypercortisolemia. However, gadolinium-enhanced MRI revealed no evidence of pituitary adenoma. The patient recovered from hypokalemia following an administration of magnesium in addition to potassium, which was accompanied by potassium over-excretion improvement. After being discharged, serum potassium level was maintained within a normal range with only magnesium infusion treatment. Furthermore, alcohol intake was reduced from 160 to 20 g/day and an endocrinological re-examination after that restriction showed normal cortisol regulation. The patient was diagnosed with pseudo-Cushing’s syndrome induced by alcohol abuse. Serum potassium level was maintained within a normal range even after discontinuation of magnesium supplementation. Our findings in this case indicate that pseudo-Cushing’s syndrome in conjunction with hypomagnesemia may be involved in development of hypokalemia in patients with chronic alcoholism.


  • Open Access

    Plasma brain-derived neurotrophic factor concentration is a predictor of chronic kidney disease in patients with cardiovascular risk factors – Hyogo Sleep Cardio-Autonomic Atherosclerosis study

    by Masafumi Kurajoh, Manabu Kadoya, Akiko Morimoto, Akio Miyoshi, Akinori Kanzaki, Miki Kakutani-Hatayama, Kae Hamamoto, Takuhito Shoji, Yuji Moriwaki, Tetsuya Yamamoto, et al.

    Brain-derived neurotrophic factor (BDNF) has been shown to have protective effects against cardiovascular diseases and death through neural and non-neural pathways via tropomyosin-related kinase B signaling. However, it is not known whether plasma BDNF concentration is a predictor of chronic kidney disease (CKD). This study was conducted as a prospective cohort study as part of the Hyogo Sleep Cardio-Autonomic Atherosclerosis. We measured plasma BDNF concentration in 324 patients without CKD, defined as an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2, and with cardiovascular risk factors. As potential confounders, sleep condition, nocturnal hypertension, and autonomic function were quantitatively examined. The patients were followed for a median 37 months (range 2–59 months) and occurrence of CKD was noted. Plasma BDNF concentration was significantly and independently associated with CKD development, which occurred in 38 patients (11.7%). Kaplan-Meier analysis revealed that patients with reduced plasma BDNF concentration exhibited a significantly (p = 0.029) greater number of CKD events as compared to those with a higher concentration. Moreover, comparisons of key subgroups showed that the risk of CKD in association with low plasma BDNF concentration was more prominent in patients with a greater reduction of nocturnal systolic blood pressure, better movement index, higher standard deviations of the NN(RR) interval or average NN(RR) interval for each 5-minute period, and without past cardiovascular disease events, smoking habit, or albuminuria. Plasma BDNF concentration is an independent predictor for development of CKD in patients with cardiovascular risk factors.


  • Plasma leptin concentration is associated with fatigue severity in patients with cardiovascular risk factors – HSCAA study

    by Masafumi Kurajoh, Manabu Kadoya, Akiko Morimoto, Mariko Naka, Akio Miyoshi, Akinori Kanzaki, Miki Kakutani-Hatayama, Kae Hamamoto, Takuhito Shoji, Yuji Moriwaki, et al.


  • A case of anti-aminoacyl tRNA synthetase antibody syndrome complicated by hemophagocytic syndrome

    by Kota Azuma, Masao Tamura, Masafumi Kurajoh, Yuji Hosono, Ran Nakajima, Kazuyuki Tsuboi, Takeo Abe, Chie Ogita, Yuichi Yokoyama, Tetsuya Furukawa, et al.

    48歳,女性,主訴は発熱,全身倦怠感.2013年12月から38℃の発熱が出現し近医受診.間質性肺炎を指摘されるも経過観察となっていた.2014年1月に手指の皮疹,末梢血流障害が出現.成人Still病疑いと診断され,ベタメタゾン(0.5mg/day)とシクロスポリン(75mg/day)でコントロールされていた.2014年11月に全身倦怠感,発熱,頭痛などの症状出現.頭部MRIで下垂体腫大認め,採血でも抗下垂体抗体陽性のため自己免疫性下垂体炎と診断.当院での治療を希望されたため2015年5月当院内分泌科入院となったが,活動性は乏しく,無治療経過観察となった.発熱・間質性肺炎・レイノー症状・両側大腿内側部の筋痛などの症状あることから膠原病が疑われ,精査加療目的に当科転科となった.成人Still病は診断基準を満たすものではなく,現在の病態を正確に把握するため,ベタメタゾンとシクロスポリンは中止とした.入院時血液検査は抗ARS抗体陽性,筋原性酵素上昇を認めた.間質性肺炎を伴う抗ARS症候群と診断し,mPSL 500mg×3日間投与し,後療法はプレドニゾロン(PSL)35mg/dayで開始とした.その後症状は治まっていたが,3日後に再度発熱・筋痛が出現し汎血球減少も伴った.骨髄穿刺で貪食像を認めたため,血球貪食症候群(HPS)と考え,増悪に起因すると考え125mg/dayで再開.その後は発熱・筋痛は消失し再燃を認めていない.また汎血球減少に関しても治療後は3系統とも血球の改善を認めた.


  • Open Access

    Plasma leptin level is associated with cardiac autonomic dysfunction in patients with type 2 diabetes: HSCAA study

    by Masafumi Kurajoh, Hidenori Koyama, Manabu Kadoya, Mariko Naka, Akio Miyoshi, Akinori Kanzaki, Miki Kakutani-Hatayama, Hirokazu Okazaki, Takuhito Shoji, Yuji Moriwaki, et al.

    It has been shown that visceral fat accumulation is associated with autonomic dysfunction, though the precise mechanism remains unclear. A recent basic study found that leptin can directly modulate autonomic function through the dorsomedial hypothalamus in relation to obesity. Here, we investigated the mutual relationships among plasma leptin, visceral fat accumulation, and cardiac autonomic dysfunction in patients with type 2 diabetes. This cross-sectional study included 100 diabetic patients, and 100 age- and gender-matched non-diabetic patients with cardiovascular risk factors. Plasma leptin and soluble leptin receptor levels, visceral fat area (VFA), and heart rate variability (HRV) were determined in addition to classical cardiovascular risk factors. In the type 2 diabetic patients, VFA was significantly (p < 0.05) and inversely associated with HRV parameters (SDNN: r = −0.243; SDANN5: r = −0.238), while the plasma level of leptin, but not soluble leptin receptor, was also significantly (p < 0.05) and inversely associated with HRV parameters (SDNN: r = −0.243; SDANN5: r = −0.231). Multiple regression analysis showed that plasma leptin was significantly associated with SDNN and SDANN5 independent of other factors, including age, gender, presence of hypertension and dyslipidemia, duration of diabetes, HbA1c, and eGFR. Furthermore, the relationship of leptin with SDNN and SDANN5 (β = −0.279 and −0.254, respectively) remained significant (p < 0.05) after adjustment for VFA. In patients without diabetes, no significant associations were observed between leptin and any of the HRV parameters. Hyperleptinemia may be involved in cardiac autonomic dysfunction in patients with type 2 diabetes and visceral obesity.